Unstoppable Skyler Fisher: Triumphing Across Continents with CMT

by | Feb 27, 2024 | 0 comments

Unstoppable Skyler Fisher: Triumphing Across Continents with CMT

In the fast-paced world of para triathlons, one name stands out among the rest: Skyler Fisher, a dynamic 19-year-old powerhouse representing Team USA. Despite facing formidable challenges, Skyler’s indomitable spirit propels her to compete on the global stage, inspiring countless hearts along the way.

Her journey has been anything but easy. Battling lower extremity issues for months, the source of her struggles was finally identified as Charcot-Marie-Tooth type 2A (CMT2A). But did this setback deter her? Absolutely not. Skyler’s determination only burned brighter, igniting a flame of resilience within her that refused to be extinguished.

In the year 2023 alone, Skyler’s tenacity carried her across continents, from the picturesque landscapes of Italy and Spain to the rugged terrains of the United States. Now, poised on the brink of a new season, she prepares to kick-start her conquest once again, beginning in the vibrant city of Miami for the Continental Championships this March.

But Skyler’s ambitions stretch far beyond merely competing; she harbors dreams of securing crucial ranking points that will catapult her towards the pinnacle of para sports—the Paralympic Games. With her sights set on illustrious destinations like Japan, Great Britain, and Canada, as well as the prestigious World Championships in Spain, there’s no limit to her aspirations.

Yet, for Skyler, it’s not just about personal triumphs on the racecourse. Each stride she takes serves a greater purpose—a mission to shatter stereotypes and defy expectations surrounding disabilities. By fearlessly navigating the triathlon circuit, she becomes a beacon of hope, proving that barriers can be overcome and dreams realized, regardless of the obstacles of CMT.

Moreover, Skyler’s advocacy extends beyond the finish line. With unwavering resolve, she seeks to raise awareness about Charcot Marie Tooth Disease, a cause close to her heart. Through her platform, she amplifies the voices of those affected, driving forward the quest for a cure and offering solace to individuals grappling with similar challenges.

As the world eagerly anticipates the next chapter of Skyler Fisher’s remarkable odyssey, one thing remains certain: her journey is far from over. With each stroke, pedal, and stride, she continues to inspire, and support CMT research and programs as the newest member of Team CMT for the Hereditary Neuropathy Foundation. 

Team CMT is a grassroots community fundraising program with hundreds of participants across the globe. Members can choose to donate, participate in HNF-partnered events or host their own events. No action is too small! Every bit of effort can have an impact on individuals like Skyler and the CMT community.

Skyler next event: March 8 at the 2024 Americas Paratriathlon Championships Miami.

Learn more on this topic

Related Blog Posts

March 29, 2015: OK…Now What?

March 29, 2015: OK…Now What?

January 15th 2015. That was the day I got my official invite to the race, that was the day of no turning back, that was the day I realized I was going to riding my bike a lot this spring and summer, a whole lot!

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news